Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
Become a Member | Sign in
Home>News>This Article

CSP Introduces Activ-Blister® Technology for Pharmaceutical Manufacturers

Published: Monday, October 22, 2012
Last Updated: Monday, October 22, 2012
Bookmark and Share
Innovative desiccated blister packaging protects moisture and oxygen-sensitive solid dose pharmaceuticals for better product performance.

CSP Technologies has announced the global launch of its Activ-Blister® desiccated blister packaging for the pharmaceutical industry.

Activ-Blister® desiccant film technology controls the internal atmosphere of each individual blister cavity, protecting moisture and oxygen-sensitive solid dose pharmaceuticals.

The result is optimized product stability, increased shelf-life, and greater consumer convenience.

Activ-Blister® also helps ensure consumer safety, because unlike conventional desiccants, there is no chance of accidental ingestion.

Activ-Blister® offers manufacturers superior flexibility in packaging design, providing an opportunity to differentiate their products.

By eliminating the need for traditional desiccant tablets in separate blister wells, Activ-Blister® allows for a slimmer, more convenient packaging form-factor while simplifying the end-user experience.

In addition, by featuring product protection without increased blister size, Activ-Blister® provides manufacturers with potential cost savings through reduced material usage, freight costs and fuel consumption.

“Activ-Blister® is an entirely new approach to protecting pharmaceuticals with specialized packaging that can build a unique identity for brands,” according to Dan L’Ecuyer, Vice President of Sales & Marketing at CSP Technologies.

L’Ecuyer continued, “Rather than use a desiccant chip inside a separate well in a blister, our proven technologies provides all the protection without increasing blister size and material or shipping costs.”

CSP’s patented technology integrates precise desiccant, gas-absorption, and sealing properties into the blister-pack itself, extending shelf life and product performance.

Activ-Blister® exhibits excellent performance capacity with moisture absorption up to 20mgs and oxygen scavenging up to 30ccs.

In addition, CSP’s Activ-Blister®® technology is available in a variety of sizes, including all type of round tablets and capsules up to size 0, with either multilayer barrier films or aluminum foil blisters to provide protection from both moisture and oxygen.

“Safely preserving drug potency and extending shelf life are high priorities for pharmaceutical manufacturers, and for the patients who rely on their products,” says L’Ecuyer.

“Activ-Blister®, CSP’s breakthrough solid dose packaging technology provides a strong product solution that meets customer needs while also safeguarding patient health.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Drug May Prevent Life-Threatening Muscle Loss in Advanced Cancers
New data describes how an experimental drug can stop life-threatening muscle wasting (cachexia) associated with advanced cancers and restore muscle health.
Chemical Design Made Easier
Rice University scientists prepare elusive organocatalysts for drug and fine chemical synthesis.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.
Giant Molecules Inhibit Ebola Infection
European researchers have designed a "giant" molecule formed by thirteen fullerenes covered by carbohydrates which, by blocking this receptor, are able to inhibit the cell infection by an artificial ebola virus model.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Fighting Pain with Ketamine
Researchers at the Texas A&M Health Science Center are using ketamine, a drug that already exists as an anesthetic, to treat pain.
Possible New Treatment for Neurodegenerative Diseases Found
Researchers at the University of Liverpool have found that a well-established anti-epileptic drug could also be used as a treatment for neurodegenerative diseases.
Breast Cancer Drug Beats Superbug
Tamoxifen helps white blood cells clear multidrug-resistant bacteria in lab and mouse studies.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos